Publications by authors named "Valerio Renzelli"

Diabetes and cancer are two of the most common public health concerns worldwide. The complex interplay of these two conditions is a growing area of research, as patients with diabetes are at increased risk for developing cancer, and vice versa. Furthermore, both patient populations show increased risk of many communicable infectious diseases and their adverse consequences, while vaccination can play a crucial role in their prevention, improving patient outcomes.

View Article and Find Full Text PDF

Background: The aim of our retrospective study was to describe the immunophenotypic characteristics of neuroendocrine breast neoplasm (BNEN), a peculiar and rare type of breast carcinoma.

Methods: Pathological data from 51 patients affected by BNEN were retrospectively evaluated, and 44 patients were considered eligible (7 patients with incomplete data were excluded). The patients were followed in six different Italian hospitals between 2009 and 2019.

View Article and Find Full Text PDF
Article Synopsis
  • - A 72-year-old male with a history of advanced tongue cancer was found to have a large left adrenal mass during follow-up, which raised suspicion for metastasis.
  • - After surgical removal, the mass was diagnosed as poorly differentiated hepatocellular carcinoma (HCC), despite no primary liver tumor being identified during further investigations.
  • - The case highlights the importance of considering adrenal metastasis in cancer patients, as it can lead to the unexpected discovery of another underlying malignancy, such as HCC, especially in the context of liver cirrhosis.
View Article and Find Full Text PDF
Article Synopsis
  • Immunotherapy using immune checkpoint inhibitors (ICI) is becoming common in cancer treatment, but managing related endocrine side effects can be challenging.
  • Different scientific societies have varying guidelines concerning when to conduct endocrine testing for patients undergoing this therapy.
  • A panel of experts from several Italian medical associations has developed a straightforward and practical checklist for assessing endocrine and metabolic health in cancer patients receiving immunotherapy.
View Article and Find Full Text PDF

Aim: To conduct a meta-analysis of randomized clinical trials (RCTs) to investigate whether there is an association between glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment and thyroid cancer.

Materials And Methods: In this meta-analysis of RCTs, we included studies comparing a GLP-1RA with any comparator, lasting at least 52 weeks, and reporting the incidence of adverse events independently of the principal endpoint and population. All cases of thyroid cancer were collected.

View Article and Find Full Text PDF

There is increasing evidence of the role of endocrine disruptors (EDs) derived from commonly employed compounds for manufacturing and processing in altering hormonal signaling and function. Due to their prolonged half-life and persistence, EDs can usually be found not only in industrial products but also in households and in the environment, creating the premises for long-lasting exposure. Polybrominated diphenyl ethers (PBDEs) are common EDs used in industrial products such as flame retardants, and recent studies are increasingly showing that they may interfere with both metabolic and oncogenic pathways.

View Article and Find Full Text PDF
Article Synopsis
  • Corticosteroids (CSs) are commonly used in cancer treatment, effective for inducing cell death in blood cancers and managing allergic reactions or treatment-related symptoms.
  • Despite their benefits for patients and healthcare providers, CSs can cause potential adverse effects during and after treatment, warranting careful use in clinical settings.
  • The article reviews expert opinions on CSs, including their mechanisms, therapeutic uses, and side effects, aiming to clarify existing uncertainties around their use in oncology.
View Article and Find Full Text PDF

Lenvatinib treatment has shown a significant improvement in progression-free survival in patients with metastatic, progressive, radioiodine-refractory differentiated thyroid cancer, although its use is associated with considerable toxicity. Fatigue is one of the most frequent adverse events (AEs). It has been reported that adrenal insufficiency (AI) may be involved in lenvatinib-related fatigue.

View Article and Find Full Text PDF

Obesity, whose prevalence is pandemic and continuing to increase, is a major preventable and modifiable risk factor for diabetes and cardiovascular diseases, as well as for cancer. Furthermore, epidemiological studies have shown that obesity is a negative independent prognostic factor for several oncological outcomes, including overall and cancer-specific survival, for several site-specific cancers as well as for all cancers combined. Yet, a recently growing body of evidence suggests that sometimes overweight and obesity may associate with better outcomes, and that immunotherapy may show improved response among obese patients compared with patients with a normal weight.

View Article and Find Full Text PDF

The incidence of differentiated thyroid cancer has been increasing in the last decades all over the world. Such a steady growth cannot be entirely attributable to more intensive thyroid nodule screening and more sensitive diagnostic procedures. Several environmental factors have changed with sufficient rapidity in the same time frame and may represent credible candidates for this increase.

View Article and Find Full Text PDF